$90m IPO Sets Up Sweden's Calliditas For Phase III Readout
Biotech Sector Listings Defying Pandemic
Executive Summary
The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.
You may also be interested in...
Targeting Exciting Inflammasome Field, NodThera Raises $55m
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
‘Follow The Money’: Sweden’s Calliditas Plans US Listing
Sweden’s Calliditas plans a US IPO to better position itself ahead of this year’s pivotal readout of its orphan drug Nefecon in inflammatory renal disease IgA nephropathy.
Operation Warp Speed Spreads Its Bets With $1.6bn Novavax Deal
Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a stronger contender.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports